For the quarter ending 2026-03-31, RSSS had -$212,384 decrease in cash & cash equivalents over the period. $1,003,925 in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Adjustment to contingent earnout liability | - | 278,637 | 317,966 | 1,748,526 |
| Net income (loss) | 860,206 | 546,919 | 749,387 | 1,265,553 |
| Depreciation and amortization | 312,402 | 316,425 | 316,066 | 1,245,362 |
| Stock options expense | 90,556 | 90,556 | 58,706 | 205,457 |
| Restricted common stock expense | 158,052 | 122,893 | 153,776 | 1,518,104 |
| Modification cost of accelerated vesting of restricted common stock | - | - | - | 0 |
| Accreted interest expense | 843,129 | - | - | - |
| Accounts receivable | 1,940,306 | -1,238,010 | -292,053 | 341,434 |
| Prepaid expenses and other current assets | 185,101 | -12,186 | 140,004 | -63,296 |
| Prepaid royalties | 90,271 | -38,283 | 79,513 | -1,066,312 |
| Accounts payable and accrued expenses | 310,982 | -1,194,631 | 158,728 | -1,426,282 |
| Deferred revenue | 1,244,927 | -65,221 | -720,046 | 1,678,272 |
| Net cash provided by operating activities | 1,007,973 | 1,384,057 | 1,107,119 | 7,023,166 |
| Purchase of property and equipment | 4,048 | 7,022 | 17,539 | 19,261 |
| Payment for acquisition, net of cash acquired-Resolute Innovation Inc | - | - | - | 0 |
| Payment for acquisition, net of cash acquired-Scite Inc. | - | - | - | 0 |
| Net cash used in investing activities | -4,048 | -7,022 | -17,539 | -19,261 |
| Proceeds from the exercise of stock options | 0 | 157,500 | - | 180,800 |
| Common stock repurchase | 7,836 | 16,162 | 23,387 | 934,577 |
| Payment of contingent acquisition consideration - scite and fiz | 1,211,869 | 1,216,537 | 1,337,857 | 124,107 |
| Net cash used in financing activities | -1,219,705 | -1,075,199 | -1,361,244 | -877,884 |
| Effect of exchange rate changes | 3,396 | 5,181 | 115 | 1,260 |
| Net increase (decrease) in cash and cash equivalents | -212,384 | 307,017 | -271,549 | 6,127,281 |
| Cash and cash equivalents, beginning of period | 12,262,780 | 11,955,763 | 12,227,312 | 6,100,031 |
| Cash and cash equivalents, end of period | 12,050,396 | 12,262,780 | 11,955,763 | 12,227,312 |
Research Solutions, Inc. (RSSS)
Research Solutions, Inc. (RSSS)